Vext Science Inc (VEXTF) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Vext Science Inc $0.65, price $0.17, upside +275.1%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Vext Science Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0728 – $0.7016 · fair‑value band $0.3800 – $1.03 · the $0.1733 price screens below the $0.6500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Vext Science in your weekly email
Every Wednesday you see whether Vext Science is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vext Science, Inc., through its subsidiaries, engages in integrated cannabis operations in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, edibles, and extracts.
Show more
Vext Science, Inc., through its subsidiaries, engages in integrated cannabis operations in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, edibles, and extracts. The company also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen, Pure Touch, Appalachian Pharm, Herbal Wellness, Prism, Firebrand, and Revibe brands. The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019. Vext Science, Inc. was incorporated in 2015 and is headquartered in Phoenix, Arizona.
Stock analysis
Vext Science Inc (VEXTF) currently trades at $0.1733, while our model-based Fair Value estimate is $0.6500, implying the stock looks roughly 73.3% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.5400 per share, and 9 of the 10 models we run sit above the $0.1733 price.
Bear case: the Asset-Based group reads lowest at $0.1500, and 1 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.3800 (bear) to $1.03 (bull), the price of $0.1733 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Vext Science Inc reported revenue of $51.4M in FY2025 versus $37.2M in FY2021, a compound +8.4%/yr. Reported net income was −$18.0M in FY2025.
Key figures
Market cap $42.9M · P/S ratio 0.87 · EPS (TTM) $−0.0600 · Net margin −35.0% · Return on equity −24.5% · Return on assets (EBIT) −0.1% · Revenue (TTM) $52.0M · Revenue growth (YoY) +5.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 37% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 275%, VEXTF screens cheaper than that median.
Fair Value models
Bear $0.3800Fair Value $0.6500Bull $1.03
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+42.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.8%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
12.8% (2020) → −13.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −9.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+200% · Top 25%
Profitability
Return on assets−2% · Bottom 25%
Net margin (TTM)−30% · Bottom 25%
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth5% · Above median
Balance sheet
Debt / equity0.43× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.78× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Vext Science Inc (VEXTF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.6500 versus a price of $0.1733, about +275% upside (undervalued).
What is the fair value of VEXTF?
Our model-based fair value for Vext Science Inc is $0.6500 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.1733.
What is the quality score of VEXTF?
Vext Science Inc has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vext Science Inc (VEXTF)?
Our model-based price target is the fair value of $0.6500 (as of Sep 23, 2026) from 10 valuation models. Cautious scenario $0.3800, optimistic scenario $1.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Vext Science Inc stock forecast for 2026?
Our models put fair value at $0.6500, about +275% upside versus a price of $0.1733 (undervalued). Cautious scenario $0.3800, optimistic scenario $1.03. The calculation is refreshed regularly with new filings.
What is the revenue of Vext Science Inc (VEXTF)?
Vext Science Inc reported trailing-twelve-month revenue of about $52.0M (latest available figure, as of Sep 23, 2026).
What growth is priced into Vext Science Inc (VEXTF)?
For today's price to be fair in a discounted-cash-flow model, Vext Science Inc would have to grow free cash flow by -7.3 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.3 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of VEXTF use?
Our models discount Vext Science Inc at 9.2 %: a base by market capitalisation (nano), damped by beta 0.76, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vext Science Inc that is -7.3 % per year a year over ten years, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Vext Science Inc (VEXTF) delivered so far?
Over the past 5 years revenue at Vext Science Inc grew +15.3 % a year. The price currently implies -7.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vext Science Inc (VEXTF) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Vext Science Inc (-7.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vext Science Inc (VEXTF)?
The free-cash-flow yield on the price is 18.98 %: that much free cash flow Vext Science Inc produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vext Science Inc (VEXTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vext Science Inc it is $0.6500 per share (as of Sep 23, 2026), against a price of $0.1733. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Vext Science Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, VEXTF trades below its calculated fair value: price $0.1733, fair value $0.6500, a gap of about +275% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VEXTF?
No. The price is what the market pays today ($0.1733); the fair value is what the company's own numbers justify ($0.6500). For Vext Science Inc the two are $0.4767 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vext Science Inc worth?
The market values Vext Science Inc at about $42.9M (market capitalisation, as of Sep 23, 2026). Per share that is $0.1733; our models calculate a fair value of $0.6500 per share.
What do the bullish and bearish scenarios say about VEXTF?
Our models span a range for Vext Science Inc: cautious scenario $0.3800, base $0.6500, optimistic $1.03 per share (as of Sep 23, 2026, price $0.1733). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vext Science Inc (VEXTF)?
Balance-sheet figures for Vext Science Inc (as of Sep 23, 2026): return on equity −24.5%, debt of 0.43 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is VEXTF from its 52-week high?
Vext Science Inc trades at $0.1733, about 37% below its 52-week high of $0.2750 and 16% above the low of $0.1500 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6500 is for.
Which stocks are comparable to Vext Science Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vext Science Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.1733, calculated fair value $0.6500 (+275%), Quality Score 48/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VEXTF calculated?
We run Vext Science Inc through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Vext Science Inc currently trades 275 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vext Science Inc (VEXTF)?
The closing price on Sep 23, 2026 was $0.1733. Our model-based fair value is $0.6500, about +275% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vext Science Inc right now?
The price is below even our cautious bear case ($0.3800). The market is more pessimistic than our downside scenario. The model range is unusually wide ($0.3800 to $1.03). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Vext Science Inc
How large is the market capitalisation of Vext Science Inc (VEXTF)?
The market capitalisation of Vext Science Inc is $42.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vext Science Inc (VEXTF)?
The price-to-sales ratio of Vext Science Inc is 0.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vext Science Inc (VEXTF)?
Earnings per share at Vext Science Inc are $−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vext Science Inc (VEXTF)?
The net margin of Vext Science Inc is −35.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vext Science Inc (VEXTF)?
The return on equity (ROE) of Vext Science Inc is −24.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vext Science Inc (VEXTF)?
On an EBIT basis the return on assets of Vext Science Inc is −0.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Vext Science Inc (VEXTF)?
Revenue at Vext Science Inc is growing +5.2% versus a year earlier (3y avg +13.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vext Science Inc (VEXTF)?
Earnings per share at Vext Science Inc are growing −39.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Vext Science Inc (VEXTF) carry?
The net debt of Vext Science Inc is $25.9M (fiscal year 2025, ≈ 3.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vext Science Inc in the live analysis
One click puts Vext Science Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026